Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06673641 · ClinicalTrials.gov registry record · Phase 1
A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.
A Phase 1 study, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Phase 1
- Development phase
- 382
- Enrollment target
NCT06673641 is a Phase 1 study that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 382 participants.
The verdict
NCT06673641, a Phase 1 study, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 382 participants
- Enrollment target
Study Summary
To demonstrate the efficacy, therapeutic equivalence and safety of Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel in the treatment of acne vulgaris.
Interventions
- DRUG Placebo Control
- DRUG Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2%
- DRUG CABTREO Topical Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 382 participants |
| Start Date | 2024-05-13 |
| Est. Completion | 2024-09-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06673641
The ClinicalTrials.gov registry entry for NCT06673641 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 382 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo Control is the first listed.
NCT06673641 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06673641 about?
NCT06673641 is a clinical study titled "A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.". To demonstrate the efficacy, therapeutic equivalence and safety of Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel in the treatment of acne vulgaris.
What is the current status of trial NCT06673641?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 382 participants. The study started on 2024-05-13. Estimated completion is 2024-09-03.
What interventions are being tested in trial NCT06673641?
The interventions under investigation include: Placebo Control (DRUG), Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (DRUG), CABTREO Topical Gel (DRUG).
Who is sponsoring clinical trial NCT06673641?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.